Top

Indian Journal of Otolaryngology and Head & Neck Surgery

04-01-2025 | Cytostatic Therapy | Original Article

Impact of Induction Chemotherapy Before Radical Chemoradiation in Oral Cavity Squamous Cell Carcinoma: A Tertiary Centre Experience

Authors: Sauharda Lohani, Gerim Prasai, Sarthak Tandon, Parveen Ahlawat, Varghese Antony, Akash R. Bellige, Vibhor Patodi, Shaifali Mahajan, Preetha Umesh, Apoorva Nayak, Munish Gairola

Published in: Indian Journal of Otolaryngology and Head & Neck Surgery

Abstract

Advanced Oral Cavity Squamous Cell Carcinoma (OSCC) poses challenges for upfront resection. While surgery followed by adjuvant treatment is standard, induction chemotherapy is explored for better resectability and organ preservation. Its efficacy in unresectable cases is still uncertain and yet to be proven. A retrospective study was done at our institute by reviewing the institutional database from January 2018 to December 2020, where patients with biopsy proven OSCC who were considered unresectable disease but treated with curative intention recruited. All the patients recruited were divided into two cohorts: Radical CCRT (Arm A) or Induction Chemotherapy (IC) followed by Chemo Radiotherapy (CCRT) (Arm B) were evaluated. The patients were analyzed for progression free survival (PFS) and Overall Survival (OS). One hundred and eighty (180) patients of locally advanced unresectable OSCC were treated with curative intent. However, data of 22 (12%) patients were excluded because of incomplete data in the database. Of remaining 158 patients, 120 (76%) and 38 (24%) were divided into arm A and B, respectively. Baseline characteristics were statistically similar in both arms except for sub site distribution with higher percentage of buccal mucosa primary [25.8% vs 42.1% in arm A vs. B respectively, p-value 0.047]. With a median follow-up of 16 (range 2–73) months, the Progression Free Survival (PFS) observed was 11 vs. 12 months [p-value 0.460] and Overall Survival (OS) was 16 vs. 17 months [p-value 0.450] in arms A and B respectively. Our study showed IC doesn’t have benefit in terms of PFS or OS compared to upfront CCRT in unresectable OSCC treated in a definitive setting. However, a more robust data and literature is required to come up with a clear answer for this clinical question.

World Health Organization. Global health estimates 2020: deaths by cause, age, sex, by country and by region, 2000–2019.

Xie L, Shang Z (2022) Burden of oral cancer in Asia from 1990 to 2019: estimates from the global burden of disease 2019 study. PLoS ONE 17(3):e0265950. https://doi.org/10.1371/journal.pone.0265950.PMID:35324990;PMCID:PMC8947401CrossRefPubMedPubMedCentral

Sankaranarayanan R, Ramadas K, Thomas G, Muwonge R, Thara S, Mathew B, Rajan B (2005) Effect of screening on oral cancer mortality in Kerala, India: a cluster-randomised controlled trial. Lancet 365(9475):1927–1933. https://doi.org/10.1016/S0140-6736(05)66658-5CrossRefPubMed

Coelho KR (2012) Challenges of the oral cancer burden in India. J Cancer Epidemiol 2012:1–17. https://doi.org/10.1155/2012/701932CrossRef

Patil VM, Prabhash K, Noronha V, Joshi A, Muddu V, Dhumal S, Arya S, Juvekar S, Chaturvedi P, Chaukar D, Pai P, Kane S, Patil A, Agarwal JP, Ghosh-Lashkar S, Dcruz A (2014) Neoadjuvant chemotherapy followed by surgery in very locally advanced technically unresectable oral cavity cancers. Oral Oncol 50(10):1000–1004. https://doi.org/10.1016/j.oraloncology.2014.07.015CrossRefPubMed

Katna R, Kalyani N, Singh S, Bhosale B (2020) Mumbai oncology group: head and neck. Compartmental clearance of infratemporal fossa for T4b carcinoma of buccal mucosa/alveolus: clinical outcomes. Indian J Surg Oncol 11(2):316–320. https://doi.org/10.1007/s13193-020-01057-yCrossRefPubMedPubMedCentral

Madera M, Tirado Amador L, Leal AC (2021) Therapeutic options in unresectable oral squamous cell carcinoma: a systematic review. Cancer Manag Res 25(13):6705–6719. https://doi.org/10.2147/CMAR.S283204.PMID:34471384;PMCID:PMC8403568CrossRef

Schwartz LH, Litière S, de Vries E, Ford R, Gwyther S, Mandrekar S, Shankar L, Bogaerts J, Chen A, Dancey J, Hayes W, Hodi FS, Hoekstra OS, Huang EP, Lin N, Liu Y, Therasse P, Wolchok JD, Seymour L (2016) RECIST 1.1-update and clarification: from the RECIST committee. Eur J Cancer 62:132–137. https://doi.org/10.1016/j.ejca.2016.03.081CrossRefPubMedPubMedCentral

Mahajan A, Agarwal U, Patil VM, Patil V, Vaish R, Noronha V, D’Cruz AK, Chaturvedi SSP, Laskar SG, Sable N, Janu A, Patil A, Menon M, Rane S, Mittal N, Joshi A, Menon N, Prabhash K (2022) Proposed sub-compartmentalization of high infratemporal fossa involvement in gingivobuccal cancers and its impact on clinical outcome and staging: a narrative review. Cancer Res, Stat, Treat 5(2):269–275. https://doi.org/10.4103/crst.crst_293_21CrossRef

10.

Bossi P, Lo Vullo S, Guzzo M, Mariani L, Granata R, Orlandi E, Locati L, Scaramellini G, Fallai C, Licitra L (2014) Preoperative chemotherapy in advanced resectable OCSCC: long-term results of a randomized phase III trial. Ann Oncol 25(2):462–466. https://doi.org/10.1093/annonc/mdt555CrossRefPubMed

11.

Chaukar D, Prabash K, Rane P, Patil VM, Thiagarajan S, Ghosh-Laskar S, Sharma S, Pai PS, Chaturvedi P, Pantvaidya G, Deshmukh A, Nair D, Nair S, Vaish R, Noronha V, Patil A, Arya S, D’Cruz A (2022) Prospective phase II open-label randomized controlled trial to compare mandibular preservation in upfront surgery with neoadjuvant chemotherapy followed by surgery in operable oral cavity cancer. J Clin Oncol 40(3):272–281. https://doi.org/10.1200/JCO.21.00179CrossRefPubMed

12.

Hitt R, López-Pousa A, Martínez-Trufero J, Escrig V, Carles J, Rizo A, Isla D, Vega ME, Martí JL, Lobo F, Pastor P, Valentí V, Belón J, Sánchez MA, Chaib C, Pallarés C, Antón A, Cervantes A, Paz-Ares L, Cortés-Funes H (2005) Phase III study comparing cisplatin plus fluorouracil to paclitaxel, cisplatin, and fluorouracil induction chemotherapy followed by chemoradiotherapy in locally advanced head and neck cancer. J Clin Oncol 23(34):8636–8645. https://doi.org/10.1200/JCO.2004.00.1990CrossRefPubMed

13.

Haddad R, O’Neill A, Rabinowits G, Tishler R, Khuri F, Adkins D, Clark J, Sarlis N, Lorch J, Beitler JJ, Limaye S, Riley S, Posner M (2013) Induction chemotherapy followed by concurrent chemoradiotherapy (sequential chemoradiotherapy) versus concurrent chemoradiotherapy alone in locally advanced head and neck cancer (PARADIGM): a randomised phase 3 trial. Lancet Oncol 14(3):257–264. https://doi.org/10.1016/S1470-2045(13)70011-1CrossRefPubMed

14.

Cohen EE, Karrison TG, Kocherginsky M, Mueller J, Egan R, Huang CH, Brockstein BE, Agulnik MB, Mittal BB, Yunus F, Samant S, Raez LE, Mehra R, Kumar P, Ondrey F, Marchand P, Braegas B, Seiwert TY, Villaflor VM, Haraf DJ, Vokes EE (2014) Phase III randomized trial of induction chemotherapy in patients with N2 or N3 locally advanced head and neck cancer. J Clin Oncol 32(25):2735–2743. https://doi.org/10.1200/JCO.2013.54.6309CrossRefPubMedPubMedCentral

15.

Blanchard P, Baujat B, Holostenco V, Bourredjem A, Baey C, Bourhis J, Pignon JP (2011) MACH-CH Collaborative group. Meta-analysis of chemotherapy in head and neck cancer (MACH-NC): a comprehensive analysis by tumour site. Radiother Oncol 100(1):33–40. https://doi.org/10.1016/j.radonc.2011.05.036CrossRefPubMed

16.

Noronha V, Dhanawat A, Patil VM, Menon N, Singh AK, Chaturvedi P, Pai P, Chaukar D, Laskar SG, Prabhash K (2024) Long-term outcomes of neo-adjuvant chemotherapy on borderline resectable oral cavity cancers: real-world data of 3266 patients and implications for clinical practice. Oral Oncol 148:106633. https://doi.org/10.1016/j.oraloncology.2023.106633CrossRefPubMed

17.

Foster CC, Melotek JM, Brisson RJ, Seiwert TY, Cohen EEW, Stenson KM, Blair EA, Portugal L, Gooi Z, Agrawal N, Vokes EE, Haraf DJ (2018) Definitive chemoradiation for locally-advanced oral cavity cancer: a 20-year experience. Oral Oncol 80:16–22. https://doi.org/10.1016/j.oraloncology.2018.03.008CrossRefPubMed

18.

Alzahrani R, Obaid A, Al-Hakami H, Alshehri A, Al-Assaf H, Adas R, Alduhaibi E, Alsafadi N, Alghamdi S, Alghamdi M (2020) Locally advanced oral cavity cancers: what is the optimal care? Cancer Control 27(1):1073274820920727. https://doi.org/10.1177/1073274820920727CrossRefPubMedPubMedCentral

19.

Ghi MG, Paccagnella A, Ferrari D, Foa P, Alterio D, Codecà C, Nolè F, Verri E, Orecchia R, Morelli F, Parisi S, Mastromauro C, Mione CA, Rossetto C, Polsinelli M, Koussis H, Loreggian L, Bonetti A, Campostrini F, Azzarello G, D’Ambrosio C, Bertoni F, Casanova C, Emiliani E, Guaraldi M, Bunkheila F, Bidoli P, Niespolo RM, Gava A, Massa E, Frattegiani A, Valduga F, Pieri G, Cipani T, Da Corte D, Chiappa F, Rulli E, GSTTC (Gruppo di Studio Tumori della Testa e del Collo) Italian Study Group (2017) Induction TPF followed by concomitant treatment versus concomitant treatment alone in locally advanced head and neck cancer. A phase II-III trial. Ann Oncol 28(9):2206–2212. https://doi.org/10.1093/annonc/mdx299CrossRefPubMed

20.

Patil VM, Noronha V, Joshi A, Kumar A, Dsouza H, Bhattacharjee A, Mahajan A, Sabale N, Ghosh-Laskar S, Prabhash K (2020) Chemoradiation in unresectable oral cavity cancer: a myth or reality! South Asian J Cancer 09(04):195–198. https://doi.org/10.1055/s-0041-1728225CrossRef

21.

Chang PM, Lu HJ, Wang LW, Tai SK, Chen MH, Chu PY, Yang MH (2017) Effectiveness of incorporating cetuximab into docetaxel/cisplatin/fluorouracil induction chemotherapy and chemoradiotherapy for inoperable squamous cell carcinoma of the oral cavity: a phase II study. Head Neck 39(7):1333–1342. https://doi.org/10.1002/hed.24766CrossRefPubMed

22.

Meng J, Gu QP, Meng QF, Zhang J, Li ZP, Si YM, Guo W, Zhuang QW (2014) Efficacy of nimotuzumab combined with docetaxel-cisplatin-fluorouracil regimen in treatment of advanced oral carcinoma. Cell Biochem Biophys 68(1):181–184. https://doi.org/10.1007/s12013-013-9686-5CrossRefPubMed

23.

Yen CJ, Tsou HH, Hsieh CY, Chu CY, Chiu CF, Chen CC, Tsao CJ, Tsai KY, Tsai ST, Chang JY, Chang KY (2019) Sequential therapy of neoadjuvant biochemotherapy with cetuximab, paclitaxel, and cisplatin followed by cetuximab-based concurrent bioradiotherapy in high-risk locally advanced oral squamous cell carcinoma: final analysis of a phase 2 clinical trial. Head Neck 41(6):1703–1712. https://doi.org/10.1002/hed.25640CrossRefPubMed

24.

Jacinto AA, Batalha Filho ES, Viana LS, De Marchi P, Capuzzo RC, Gama RR, Boldrini Junior D, Santos CR, Pinto GDJ, Dias JM, Canton HP, Carvalho R, Radicchi LA, Bentzen S, Zubizarreta E, Carvalho AL (2018) Feasibility of concomitant cisplatin with hypofractionated radiotherapy for locally advanced head and neck squamous cell carcinoma. BMC Cancer 18(1):1026. https://doi.org/10.1186/s12885-018-4893-5.PMID:30352576;PMCID:PMC6199702CrossRefPubMedPubMedCentral

Title: Impact of Induction Chemotherapy Before Radical Chemoradiation in Oral Cavity Squamous Cell Carcinoma: A Tertiary Centre Experience
Authors: Sauharda Lohani
Gerim Prasai
Sarthak Tandon
Parveen Ahlawat
Varghese Antony
Akash R. Bellige
Vibhor Patodi
Shaifali Mahajan
Preetha Umesh
Apoorva Nayak
Munish Gairola
Publication date: 04-01-2025
Publisher: Springer India
Keywords: Cytostatic Therapy
Oral Cancer
Oral Cavity Carcinoma
Radiotherapy
Published in: Indian Journal of Otolaryngology and Head & Neck Surgery
Print ISSN: 2231-3796
Electronic ISSN: 0973-7707
DOI: https://doi.org/10.1007/s12070-024-05315-1

Keynote webinar | Spotlight on adolescent vaping

Springer Medicine

Impact of Induction Chemotherapy Before Radical Chemoradiation in Oral Cavity Squamous Cell Carcinoma: A Tertiary Centre Experience

Abstract

Keynote webinar | Spotlight on adolescent vaping

Springer Medicine

Abstract

Please log in to get access to this content